2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1469

New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice
Abstract Number: 1470

Health-Related Quality of Life in Primary Sjogren’s Syndrome: Insights from Using PROMIS and Comparison to ESSPRI
Abstract Number: 1471

Polyautoimmunity and Major Organ Involvement Prevalence in Sjögren´s Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study
Abstract Number: 1472

Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up
Abstract Number: 1473

Syndecan-1 Is a Potential Biomarker for Salivary Glandular Function and Disease Activity in Patients with Sjögren’s Syndrome
Abstract Number: 1474

Factors Influencing the ESSPRI Index in Primary Sjögren’s Syndrome
Abstract Number: 1475

Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies
Abstract Number: 1476

Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Abstract Number: 1477

Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as – Analysis of a Non-Interventional Study in Germany
Abstract Number: 1478

Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials
Abstract Number: 1479

Multi-Symptom Impact on the EQ5D Index in Bio-naïve Active Psoriatic Arthritis Patients: An Analysis Through Week 24 of the GO-VIBRANT Study
Abstract Number: 1480

Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 1481

Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 1482

Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Abstract Number: 1483

Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].